Ticker Symbol: TOS/TSX
Shares Outstanding: 47,863,402
QUEBEC CITY, Oct. 21 /CNW Telbec/ - TSO3 Inc. ("TSO3") (TSX: TOS)
announced today that it will report financial results for the third quarter
2008 ended September 30, 2008, on Friday, October 31, 2008. TSO3 will host a
Conference Call at 11:00 A.M. (ET) the same day.
Analysts and institutional investors are invited to participate. The
numbers to dial for access are 514 807 8791 (Montréal area), 416 644-3414
(Toronto area) or the toll-free number 1 800 732-9303. Journalists and other
interested parties may listen to the live Webcast of the Conference Call
accessible via TSO3's Website at: www.tso3.com. The Webcast will be archived
for 90 days.
TSO3, founded in Québec City in 1998, specializes in the research and
development of innovative, high-performance medical instrument sterilization
technology with high commercial potential. The Company's first product, the
125L Ozone Sterilizer, is designed for sterile processing centers in the
In contrast to other methods used, the ozone sterilization process
developed and patented by TSO3 meets all standards required by the evolution
in sterilization needs, which are: significant costs savings, increased safety
for patients and hospital staff, and a "green" environmentally safe process.
The Company believes that its technology represents an advantageous
replacement solution to other low temperature sterilization processes
currently used in hospitals.
The 125L Ozone Sterilizer is cleared for commercialization by the US Food
and Drug Administration and by Health Canada. TSO3 is in commercialization
phase for this first product since 2006.
For more information about TSO3, visit the Company's Web site at
The statements in this release and oral statements made by
representatives of TSO3 relating to matters that are not historical facts
(including, without limitation, those regarding the timing or outcome of any
financing undertaken by TSO3) are forward-looking statements that involve
certain risks, uncertainties and hypotheses, including, but not limited to,
general business and economic conditions, the condition of the financial
markets, the ability of TSO3 to obtain financing on favourable terms and other
risks and uncertainties.
The TSX has neither approved nor disapproved the information contained
herein and accepts no responsibility for it.
For further information:
For further information: Marc Boisjoli, CFO, (418) 651-0003, ext. 228,
email@example.com; Frédéric Tremblay, HKDP, (514) 395-0375, ext. 234; Source: